For large, self-insured U.S. employers, their No. 1 concern related to pharmacy benefits is how to finance treatments that come with seven-figure price tags. That’s one finding of the National Business Group on Health (NBGH) 2020 Large Employers’ Health Care Strategy and Plan Design Survey, the results of which were unveiled on Aug. 13. Among the 147 employer respondents, 86% said they were either concerned or very concerned about “the impact of million-dollar treatments getting approved by the FDA,” such as Novartis’ $2.1 million spinal muscular atrophy treatment, Zolgensma (onasemnogene abeparvovec-xioi).
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.